New York is notoriously expensive. Year after year, it tops Kiplinger's list of costliest places to live. Just visiting it can cost an arm and a leg. The average daily hotel room rate is $281, and the average cost of dinner in a restaurant is $43 per person, according to the city's official marketing and tourism organization NYC & Company. Add in the cost of other meals, transportation and entertainment, and you could easily spend $500 a day in the Big Apple.
SEE ALSO: 26 Secrets to Save on TravelHowever, there are plenty of ways to keep the costs associated with a trip under control. If you're planning a visit to New York, consider these tips to save money getting there, staying there, eating there and having fun there.
Getting to New YorkTake the bus. The cheapest way to get to the city if you live on the East Coast is the bus. A one-way ticket can cost less than what you'd pay to fill up your car's gas tank. For example, an advance-purchase Greyhound bus ticket for travel in October from Raleigh, N.C., to New York cost $45 versus $52.95 to fill up a 15-gallon tank at the average East Coast gas price of $3.53 a gallon (and you'll need to fill up more than once for a drive of that distance). A one-way Amtrak train ticket for the same route would cost $90.
Top 5 Managed Healthcare Companies To Own For 2015: Roche Holding AG (RHHBY)
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.
During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.
In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.
Pharmaceuticals
Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.
Diagnostics
Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.
Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.
Advisors' Opinion:- [By George Budwell]
Reason No. 1
Perhaps the biggest reason I think Puma is exciting at these levels is because PB272 is being studied in a diverse array of breast cancers, giving the company multiple shots on goal so to speak. It's no secret that breast cancer is one of the largest market opportunities in biopharma, boasting of one of the best-selling drugs ever in Roche's (NASDAQOTH: RHHBY ) Herceptin. � - [By Keith Speights]
You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient history now, but back in 1999 the Food and Drug Administration approved Roche's (NASDAQOTH: RHHBY ) Xenical.�
- [By Dan Carroll and Max Macaluso, Ph.D.]
Glaxo's staring down some tough competition. Roche (NASDAQOTH: RHHBY ) and Bristol-Myers Squibb (NYSE: BMY ) each made hundreds of millions of dollars in sales last year after both had drugs approved for melanoma in 2011. Can Glaxo rise up to carve out a lucrative niche in this space? In the following video, Fool contributor Dan Carroll and health-care analyst Max Macaluso discuss what's in store for this company's melanoma drugs.
10 Best Cheapest Stocks To Invest In Right Now: Bank of Ozarks Inc (OZRK)
Bank of the Ozarks, Inc. is a bank holding company. The Company owns an Arkansas state chartered subsidiary bank, Bank of the Ozarks (the Bank). At December 31, 2011, the Company, through the Bank, conducted banking operations through 111 offices, including 66 offices in Arkansas, 27 in Georgia, 10 in Texas, four in Florida, two in North Carolina, and one each in South Carolina and Alabama. Subsequent to December 31, 2011, the Company opened its 11th and 12th Texas offices in Austin and The Colony. The Company also owns Ozark Capital Statutory Trust II, Ozark Capital Statutory Trust III, Ozark Capital Statutory Trust IV and Ozark Capital Statutory Trust V, all 100%-owned finance subsidiary business trusts formed in connection with the issuance of certain subordinated debentures and related trust preferred securities, and, indirectly through the Bank, a subsidiary engaged in the development of real estate, a subsidiary that owns a private aircraft and various other entities that hold foreclosed assets or tax credits or engage in other activities. Effective July 31, 2013, Bank of the Ozarks Inc acquired the entire interest of The First National Bank of Shelby.
The Company provides a range of retail and commercial banking services. Deposit services include checking, savings, money market, time deposit and individual retirement accounts. Loan services include various types of real estate, consumer, commercial, industrial and agricultural loans and various leasing services. The Company also provides mortgage lending; treasury management services for businesses, individuals and non-profit and governmental entities, including wholesale lock box services; remote deposit capture services; trust and wealth management services for businesses, individuals and non-profit and governmental entities, including financial planning, money management, custodial services and corporate trust services; real estate appraisals; credit-related life and disability insurance; automated teller machines (ATMs); telep! hone banking; online and mobile banking services, including electronic bill pay; debit cards, gift cards and safe deposit boxes, among other products and services. Through third party providers, the Company offers credit cards for consumers and businesses, processing of merchant debit and credit card transactions, and full service investment brokerage services.
On January 14, 2011, the Company, through the Bank, entered into a purchase and assumption agreement, pursuant to which the Bank acquired the former Oglethorpe Bank (Oglethorpe) with two offices in Georgia, including Brunswick and St. Simons Island. On April 29, 2011, the Company, through the Bank, entered into a purchase and assumption agreement, pursuant to which the Bank acquired the former First Choice Community Bank (First Choice) with seven offices in Georgia, including Dallas, Newnan (2), Senoia, Sharpsburg, Douglasville and Carrollton. On July 1, 2011, the Company closed one of the offices in Newnan, Georgia, and on October 26, 2011 the Company closed the office in Carrollton, Georgia.
Lending and Leasing Activities
The Company�� primary source of income is interest earned from its loan and lease portfolio and its investment securities portfolio. The Company�� portfolio of real estate loans includes loans secured by residential one- to four-family, non-farm/non-residential, agricultural, construction/land development, multifamily residential (five or more family) properties and other land loans. Non-farm/non-residential loans include those secured by real estate mortgages on owner-occupied commercial buildings of various types, leased commercial, retail and office buildings, hospitals, nursing and other medical facilities, hotels and motels, and other business and industrial properties. Agricultural real estate loans include loans secured by farmland and related improvements, including some loans guaranteed by the Farm Service Agency. Real estate construction/land development loans include loa! ns secure! d by vacant land, loans to finance land development or construction of industrial, commercial, residential or farm buildings or additions or alterations to existing structures. Included in the Company�� residential one- to four-family loans are home equity lines of credit.
The Company offers a variety of real estate loan products that are generally amortized over five to thirty years. The Company�� portfolio of consumer loans generally includes loans to individuals for household, family and other personal expenditures. The Company�� commercial and industrial loan portfolio consists of loans for commercial, industrial and professional purposes, including loans to fund working capital requirements (such as inventory, floor plan and receivables financing), purchases of machinery and equipment and other purposes. The Company offers a variety of commercial and industrial loan arrangements, including term loans, balloon loans and lines of credit with the purpose and collateral supporting a particular loan determining its structure. These loans are offered to businesses and professionals for short and medium terms on both a collateralized and uncollateralized basis. The Company obtains as collateral a lien on furniture, fixtures, equipment, inventory, receivables or other assets. The Company�� leases are primarily equipment leases for commercial, industrial and professional purposes, have terms generally ranging up to 48 months and are collateralized by a lien on the lessee�� interest in the leased property.
The Company�� portfolio of agricultural (non-real estate) loans includes loans for financing agricultural production, including loans to businesses or individuals engaged in the production of timber, poultry, livestock or crops. The Company�� agricultural (non-real estate) loans are generally secured by farm machinery, livestock, crops, vehicles or other agricultural-related collateral. A portion of the Company�� portfolio of agricultural (non-real estate) loans ! consists ! of loans to individuals which would normally be characterized as consumer loans but for the fact that the individual borrowers are primarily engaged in the production of timber, poultry, livestock or crops.
Deposits
The Company offers an array of deposit products consisting of non-interest bearing checking accounts, interest bearing transaction accounts, business sweep accounts, savings accounts, money market accounts, time deposits and individual retirement accounts. The Company acts as depository for a number of state and local Governments and Government agencies or instrumentalities. The Company�� deposits come primarily from within the Company�� trade area. As of December 31, 2011, the Company had $41 million in brokered deposits.
Other Banking Services
The Company offers an array of residential mortgage products, including long-term fixed and variable rate loans to be sold on a servicing-released basis in the secondary market. The Company originates residential mortgage loans to be resold on the secondary market primarily through its banking offices located in Arkansas��markets, many of its Texas banking offices and in certain of its acquired offices in the Southeastern United States. The Company offers a range of trust and wealth management services from its headquarters in Little Rock, Arkansas, with additional staff in Rogers, Arkansas. These trust and wealth management services include personal trusts, custodial accounts, investment management accounts, retirement accounts, corporate trust services, including trustee, paying agent and registered transfer agent services, and other incidental services. As of December 31, 2011, total trust assets were approximately $1.02 billion.
The Company offers treasury management products which are designed to provide specialized support to the treasury operations of business and public funds customers. The Company�� treasury management services include automated clearing house serv! ices (dir! ect deposit, direct payment and electronic cash concentration and disbursement), wire transfer, zero balance accounts, current and prior day transaction reporting, lock box services, remote deposit capture services, automated credit line transfer, investment sweep accounts, reconciliation services, positive pay services, credit line analysis and account analysis. It offers an online banking service for both business customers and consumers. Through this service customers can access their account information, pay bills, transfer funds, view images of cancelled checks, reorder checks, buy the United States Savings Bonds, change addresses, issue stop payment requests, receive detailed statements and handle other banking business electronically. The Company also provides businesses and consumers the option to electronically receive monthly bank statements and provides a 13-month archive of monthly statements and cancelled check images.
Advisors' Opinion:- [By Eric Volkman]
Bank of the Ozarks (NASDAQ: OZRK ) is rewarding its shareholders by paying a higher dividend. The company has declared a common stock dividend of $0.19 per share, to be handed out on July 19 to shareholders of record as of July 12. That amount is $0.02, or 12%, higher than the company's previous disbursement of $0.17 per share, which was paid in mid-April.
- [By Monica Gerson]
Bank of the Ozarks (NASDAQ: OZRK) is expected to post its Q3 earnings at $0.60 per share on revenue of $69.57 million.
Emmis Communications (NASDAQ: EMMS) is expected to report its Q2 earnings.
- [By Marc Bastow]
Arkansas-based Bank of the Ozarks (OZRK) announced a 10.5% dividend increase to 21 cents per share, payable Oct. 18 to shareholders of record as of Oct. 11. This is the 13th consecutive quarter in which OZRK has raised its dividend.
OZRK Dividend Yield: 1.77% - [By Marc Bastow]
Yet another bank, Bank of the Ozarks (OZRK) raised its dividend 4.5% to 23 cents per share, payable April 18 to shareholders of record as of April 11.
OZRK Dividend Yield: 1.37%
10 Best Cheapest Stocks To Invest In Right Now: Unisys Corporation (UIS)
Unisys Corporation provides information technology (IT) services, software, and technology that solve mission-critical problems for clients worldwide. It operates in two segments, Services and Technology. The Services segment provides outsourcing services, including management of customers� data centers, computer servers, and end-user computing environments, as well as specific business processes; systems integration and consulting services, such as assessing the security and cost effectiveness of clients� IT systems and enabling them to design, integrate, and modernize mission-critical applications; infrastructure services consisting of design, warranty, and support services for its customers� IT infrastructure, such as networks, desktops, servers, and mobile and wireless devices; and maintenance services. The Technology segment designs and develops servers and related products consisting of enterprise-class servers, which comprise the ClearPath family of servers and t he ES7000 family of Intel-based servers, as well as operating system software and middleware; and provides data center, infrastructure management, and cloud computing offerings for clients to virtualize and automate their data-center environments. The company serves public sector; financial services; and other commercial markets comprising communications and transportation. Unisys Corporation markets its products and services primarily through direct sales force, as well as through distributors and alliance partners. Unisys Corporation was founded in 1886 and is headquartered in Blue Bell, Pennsylvania.
Advisors' Opinion:- [By Jake L'Ecuyer]
Unisys (NYSE: UIS) shares tumbled 12.12 percent to $25.42 on Q1 results. Unisys reported a quarterly loss of $0.74 per share on revenue of $762.0 million.
- [By Monica Gerson]
Unisys (NYSE: UIS) is estimated to post its Q3 earnings at $0.40 per share on revenue of $854.13 million.
Harley-Davidson (NYSE: HOG) is expected to report its Q3 earnings at $0.73 per share on revenue of $1.17 billion.
- [By Alex Planes]
Originally built by Eckert and Mauchly under their own brand, UNIVAC proved so costly and time-consuming to develop that the duo sold their business to Remington-Rand -- which still operates in the computing industry today as Unisys (NYSE: UIS ) -- before completing the project. UNIVAC was designed from the ground up for business use rather than scientific calculation, and represented the first real digital threat to IBM's (NYSE: IBM ) punched-card tabulators, which had been the Census Bureau's preferred number-crunching tools for decades. However, their astronomically high cost -- $750,000 for the eight-ton machine and another $185,000 for the high-speed printer -- kept UNIVAC from becoming a big-business hit, even after it nailed the results of President Dwight Eisenhower's landslide 1952 election victory with only 1% of the vote recorded. That wasn't for lack of trying on Remington Rand's part:
- [By Evan Niu]
What: Shares of Unisys (NYSE: UIS ) have popped by as much as 13% today after the company reported earnings.
So what: Revenue of $859 million crushed the consensus estimate of $838 million. The bottom line also beat, but by less. Unisys posted non-GAAP earnings per share of $0.91, slightly ahead of the $0.90-per-share forecast.
10 Best Cheapest Stocks To Invest In Right Now: Ameresco Inc (AMRC)
Ameresco, Inc. incorporated in April 2000, is a provider of energy efficiency solutions for facilities throughout North America. The Company�� services include upgrades to a facility's energy infrastructure and the construction and operation of small-scale renewable energy plants. Its principal service is the development, design, engineering and installation of projects that reduce the energy and operations and maintenance (O&M) costs of its customers' facilities. These projects include a variety of measures customized for the facility and designed to improve the efficiency of major building systems, such as heating, ventilation, air conditioning and lighting systems. It also serves certain customers by developing and building small-scale renewable energy plants located at or close to a customer's site. Ameresco, Inc. provides its services primarily to governmental, educational, utility, healthcare and other institutional, commercial and industrial entities. The Company operates in four segments: U.S. federal, central U.S. region, other U.S. regions and Canada. In August 2011, the Company acquired APS Energy Services Company, Inc. from Pinnacle West Capital Corporation. In December 2011, it acquired the xChange Point and energy projects businesses, including automated demand response, of Energy and Power Solutions, Inc. In August 2012, the Company acquired FAME Facility Software Solutions Inc. In February 2013, it purchased all of the assets of Ennovate Corporation. In June 2013, Ameresco Inc acquired ESP, an energy management consulting company consisting of the Energy Services Partnership and ESP Response, located in Castleford, United Kingdom.
Ameresco, Inc. offers a set of services that includes the design and installation of upgrades to a facility�� energy infrastructure, the design and construction of renewable energy plants, the sale of other renewable energy products and the arranging of financing for customer projects. In September 2010, the Company acquired Quantum Engineer! ing and Development, Inc. In July 2011, the Company acquired Applied Energy Group.
Energy Efficiency Services
The Company�� services includes the design, engineering and installation of, and the arranging of financing for, equipment to improve the efficiency, and control the operation, of a building�� heating, ventilation, cooling and lighting systems. In certain projects, it also designs and constructs a central plant or cogeneration system providing power, heat and/or cooling to a building. Its projects generally range in size and scope from a one-month project to design and retrofit a lighting system to a more complex 30-month project to design and install a central plant or cogeneration system.
Renewable Energy Projects and Products
The Company�� services offering includes the development, construction and operation of, and the arrangement of financing for, small-scale renewable energy plants, as well as the sale and integration of solar energy products and systems. It has constructed and is designing and constructing a range of renewable energy plants using landfill gas (LFG), wastewater treatment biogas, solar, wind, biomass, food waste, animal waste and hydro sources of energy. As part of its renewable energy offering, it also distributes and integrates solar energy products manufactured by several vendors. Ameresco, Inc. is a distributor of photovoltaic (PV) panels, solar regulators, solar charge controllers, inverters, solar powered lighting systems, solar powered water pumps, solar panel mounting hardware and other system components. It also integrates its PV products and system components into solar solutions designed specifically for customers. It provides solar energy solutions for both on- grid applications where the solar power is used in a building connected to a utility distribution system, and for off-grid applications where the power is used directly in the device using the electricity, such as traffic signs.
Amere! sco, Inc.! also designs and constructs renewable energy plants based on wind power. In many parts of the country, available wind resources, utility net metering and local incentives can make on-site wind generation a viable solution for meeting a portion of customers' energy needs. As of December 31, 2010, the Company had completed two projects that included a wind turbine. In addition, it has constructed and was constructing, small-scale renewable energy plants based on biomass.
As of December 31, 2010, Ameresco, Inc. had constructed more than 28 renewable energy projects, and owned and operated 22 small-scale renewable energy plants. Of the owned plants, 19 are renewable LFG plants, two are waste water biogas plants and one is a solar PV installation. These 22 small-scale renewable energy plants have the capacity to generate electricity or deliver LFG producing an aggregate of 106 megawatts (MW) or megawatt-equivalents (MWE). As of December 31, 2010, the Company had signed contracts for the construction, operation and ownership of an additional six LFG plants, two biomass power and cogeneration plants and five biomass boiler projects.
The Company competes with Chevron Energy Solutions, Constellation Energy, Honeywell, Johnson Controls, Siemens Building Technologies and TAC Energy Solutions.
Advisors' Opinion:- [By Sara Murphy]
Ameresco (NYSE: AMRC ) is one of the few large, independent energy efficiency service providers. The company's principal service is the development, design, engineering and installation of projects that reduce the energy and operations and maintenance costs of its customers' facilities. Ameresco has seen declining revenues recently because of unusually long lag times in getting its projects funded, but this seems a temporary setback.
10 Best Cheapest Stocks To Invest In Right Now: Powershares S & P Small Cap Energy Portfolio (PSCE)
PowerShares S&P SmallCap Energy Portfolio (the Fund) seeks investment results that correspond generally to the price and yield performance of an index called the S&P SmallCap 600 Capped Energy Index (the Underlying Index). The Underlying Index consists of common stocks of the United States energy companies that are principally engaged in the business of producing, distributing or servicing energy-related products, including oil and gas exploration and production, refining, oil services, pipeline, and solar, wind and other non-oil-based energy. The Underlying Index is compiled, maintained and calculated by Standard & Poor's Financial Services LLC (Standard & Poor's). The Fund will normally invest at least 80% of its total assets in common stocks of small-capitalization energy companies. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Underlying Index. The Fund�� investment adviser is Invesco PowerShares Capital Management LLC. Advisors' Opinion:- [By John Udovich]
Yesterday, small cap oil and gas stock Penn Virginia Corporation (NYSE: PVA) surged 14.84% after reporting earnings and was also rising close to 6% in�pre-market trading���meaning it might be worth taking a closer look at the small cap along with the performance of ETF peers IQ Global Oil Small Cap ETF (NYSEARCA: IOIL) and PowerShares S&P SmallCap Energy Portfolio (NASDAQ: PSCE). After all, a look at the longer term chart of Penn Virginia Corporation does not reveal a pretty picture for investors over the long haul.
10 Best Cheapest Stocks To Invest In Right Now: Paradise Inc (PARF)
Paradise, Inc., incorporated in September, 1961, conducts operations through two business segments: Candied Fruit and Molded Plastics. The Candied Fruit segment is engaged in the production of candied fruit, a basic fruitcake ingredient, sold to manufacturing bakers, institutional users, and retailers for use in home baking. Based on market conditions, it is also engaged in the processing of frozen strawberry products for sale to commercial and institutional users, such as preservers, dairies and drink manufacturers. The Molded Plastics segment is engaged in the production of plastic containers for the Company�� products and other molded plastics for sale to unaffiliated customers.
During the year ended December 31, 2011, in terms of candied fruit sales, approximately 20% were shipped to manufacturing bakers and other institutional users, with the balance being sold through supermarkets and other retail outlets for ultimate use in the home. Sales to retail outlets are usually generated through registered food brokers operating in exclusively franchised territories.
The Company�� trademarks Paradise, Dixie, Mor-Fruit and Sun-Ripe are registered with the appropriate Federal and State authorities for use on the Company�� candied fruit. During 2011, the Company derived approximately 15% of its consolidated net sales from Wal-Mart Stores, Inc.
Advisors' Opinion:- [By Geoff Gannon]
What is the advantage of being a huge company? There are some. For one, we know the business is ��or was ��growable. A lot of small companies stay small because their circle of competence is small. Paradise (PARF) is an over the counter stock. It has a market cap of $10 million. And it dominates the candied fruit market in the U.S. Why isn�� the company bigger?
10 Best Cheapest Stocks To Invest In Right Now: CEPHEID(CPHD)
Cepheid, a molecular diagnostics company, engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. Its systems enable molecular testing for organisms and genetic-based diseases by automation. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors? offices. Cepheid also provides GeneXpert Infinity System for high volume testing. The company offers tests for the GeneXpert and the SmartCycler systems in the areas of healthcare associated infections, critical infectious d isease, genetics, women?s health, and oncology. These tests include U.S. Food and Drug Administration (FDA) cleared products, CE marked products, analyte specific reagents, and research use only tests in the clinical market. In the industrial market, it sells its SmartCycler system along with general use polymerase chain reaction reagents and reaction tubes. Cepheid sells its products its direct sales force and through third-party distributors worldwide. It has collaboration agreements with Novartis, Foundation for Innovative New Diagnostics, Life Technologies Corporation, and Northrop Grumman Corporation. The company was founded in 1996 and is headquartered in Sunnyvale, California.
Advisors' Opinion:- [By Jon C. Ogg]
Cepheid (NASDAQ: CPHD) was downgraded to Neutral from Buy at Bank of America Merrill Lynch, but the firm actually raised its price target to $41 (versus a $39.04 close).
- [By Sean Williams]
What: Shares of Cepheid (NASDAQ: CPHD ) , a developer of molecular diagnostic tests for both clinical and non-clinical markets, plunged as much as 11% after the company reported its second-quarter earnings results following the closing bell last night.
No comments:
Post a Comment